Using new biological understanding to improve our ability to make better medicines
Kymab was founded through a vision and a technology that could dramatically accelerate both the speed of antibody drug development and improve the quality of antibody medicines. We believe that continued creative innovation is essential to maintaining our leading position and creating unique opportunities.
We are in a uniquely fertile time for genetic discovery and we are alert to new drug targets and the application of genetic knowledge in clinical development. Our ambition is to strengthen our innovative culture, recognising the long-term competitive advantage and value this brings.
Improving the performance and adaptability of our Kymouse™ platform to enhance its ability to deliver candidate antibodies
With our Kymouse™ platform, we have a unique opportunity to generate innovative, high-value bispecific molecules
Identifying, testing and developing effective vaccines using the Kymouse™ platform as a surrogate human immune system